

(12) International Application Status Report

Received at International Bureau: 03 April 2020 (03.04.2020)

Information valid as of: 01 October 2020 (01.10.2020)

Report generated on: 20 January 2021 (20.01.2021)

(10) Publication number:

WO2020/181376

(43) Publication date:

17 September 2020 (17.09.2020)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/CA2020/050321

(22) Filing Date:

11 March 2020 (11.03.2020)

(25) Filing language:

English (EN)

(31) Priority number(s):

62/817,152 (US)

(31) Priority date(s):

12 March 2019 (12.03.2019)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C07K 16/18 (2006.01); **A61K 39/395** (2006.01); **C12N 15/13** (2006.01); **C12P 21/08** (2006.01)

(71) Applicant(s):

UNIVERSITY HEALTH NETWORK [CA/CA]; 190 Elizabeth Street R. Fraser Elliot Building - Room 1S-417 Toronto, Ontario M5G 2C4 (CA) *(for all designated states)*

(72) Inventor(s):

BROKX, Richard; c/o University Health Network 190 Elizabeth Street R. Fraser Elliot Building - Room 1S-417 Toronto, Ontario M5G 2C4 (CA)

MASON, Jacqueline M.; c/o University Health Network 190 Elizabeth Street R. Fraser Elliot Building - Room 1S-417 Toronto, Ontario M5G 2C4 (CA)

BRAY, Mark R.; c/o University Health Network 190 Elizabeth Street R. Fraser Elliot Building - Room 1S-417 Toronto, Ontario M5G 2C4 (CA)

(74) Agent(s):

BOWN, Christopher; GOWLING WLG (CANADA) LLP Suite 2600, 160 Elgin Street Ottawa, Ontario K1P 1C3 (CA)

(54) Title (EN): TSG-6 ANTIBODIES AND USES THEREFOR

(54) Title (FR): ANTICORPS ANTI-TSG-6 ET LEURS UTILISATIONS

(57) Abstract:

(EN): The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.

(FR): L'invention concerne de nouveaux anticorps anti-TSG-6, des compositions pharmaceutiques comprenant de tels anticorps, et des méthodes thérapeutiques d'utilisation de tels anticorps et compositions pharmaceutiques pour le traitement de maladies telles que le cancer ou une maladie auto-immune.

International search report:

Received at International Bureau: 03 June 2020 (03.06.2020) [CA]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,

PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))